Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 May 31;21(5):e1004393.
doi: 10.1371/journal.pmed.1004393. eCollection 2024 May.

Incidence of self-reported tuberculosis treatment with community-wide universal testing and treatment for HIV and tuberculosis screening in Zambia and South Africa: A planned analysis of the HPTN 071 (PopART) cluster-randomised trial

Affiliations
Randomized Controlled Trial

Incidence of self-reported tuberculosis treatment with community-wide universal testing and treatment for HIV and tuberculosis screening in Zambia and South Africa: A planned analysis of the HPTN 071 (PopART) cluster-randomised trial

L Telisinghe et al. PLoS Med. .

Abstract

Background: HIV is a potent risk factor for tuberculosis (TB). Therefore, community-wide universal testing and treatment for HIV (UTT) could contribute to TB control, but evidence for this is limited. Community-wide TB screening can decrease population-level TB prevalence. Combining UTT with TB screening could therefore significantly impact TB control in sub-Saharan Africa, but to our knowledge there is no evidence for this combined approach.

Methods and findings: HPTN 071 (PopART) was a community-randomised trial conducted between November 2013 to July 2018; 21 Zambian and South African communities (with a total population of approximately 1 million individuals) were randomised to arms A (community-wide UTT and TB screening), B (community-wide universal HIV testing with treatment following national guidelines and TB screening), or C (standard-of-care). In a cohort of randomly selected adults (18 to 44 years) enrolled between 2013 and 2015 from all 21 communities (total size 38,474; 27,139 [71%] female; 8,004 [21%] HIV positive) and followed-up annually for 36 months to measure the population-level impact of the interventions, data on self-reported TB treatment in the previous 12 months (self-reported TB) were collected by trained research assistants and recorded using a structured questionnaire at each study visit. In this prespecified analysis of the trial, self-reported TB incidence rates were measured by calendar year between 2014 and 2017/2018. A p-value ≤0.05 on hypothesis testing was defined as reaching statistical significance. Between January 2014 and July 2018, 38,287 individuals were followed-up: 494 self-reported TB during 104,877 person-years. Overall incidence rates were similar across all arms in 2014 and 2015 (0.33 to 0.46/100 person-years). In 2016 incidence rates were lower in arm A compared to C overall (adjusted rate ratio [aRR] 0.48 [95% confidence interval (95% CI) 0.28 to 0.81; p = 0.01]), with statistical significance reached. In 2017/2018, while incidence rates were lower in arm A compared to C, statistical significance was not reached (aRR 0.58 [95% CI 0.27 to 1.22; p = 0.13]). Among people living with HIV (PLHIV) incidence rates were lower in arm A compared to C in 2016 (RR 0.56 [95% CI 0.29 to 1.08; p = 0.08]) and 2017/2018 (RR 0.50 [95% CI 0.26 to 0.95; p = 0.04]); statistical significance was only reached in 2017/2018. Incidence rates in arms B and C were similar, overall and among PLHIV. Among HIV-negative individuals, there were too few events for cross-arm comparisons. Study limitations include the use of self-report which may have been subject to under-reporting, limited covariate adjustment due to the small number of events, and high losses to follow-up over time.

Conclusions: In this study, community-wide UTT and TB screening resulted in substantially lower TB incidence among PLHIV at population-level, compared to standard-of-care, with statistical significance reached in the final study year. There was also some evidence this translated to a decrease in self-reported TB incidence overall in the population. Reduction in arm A but not B suggests UTT drove the observed effect. Our data support the role of UTT in TB control, in addition to HIV control, in high TB/HIV burden settings.

Trial registration: ClinicalTrials.gov: NCT01900977.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Consort flow diagram showing the PC participants from all 21 HPTN 071 (PopART) communities that contributed person time to the cohort analysis.
PC, population cohort; f/u, follow-up; pyrs, person years; 1 person with unknown termination reason at PC12; 42 people with unknown termination reason at PC24 (5 [<1%] in arm A; 29 [2%] in arm B; and 8 [<1%] in arm C); *denominator the total enrolled in that arm at PC0.
Fig 2
Fig 2. Geometric mean of the cluster rates (2A to 2C) of self-reported TB treatment by year and study arm in the cohort analysis, and, geometric mean of the cluster proportions (2D to 2F) of self-reported TB treatment by PC visit and study arm in the cross-sectional analysis, among PC participants from all 21 HPTN 071 (PopART) communities.
GM, geometric mean; pyrs, person years; PC, population cohort; 2A, total population; 2B, people living with HIV; 2C, people who were HIV negative; 2D, total population; 2E, people living with HIV; 2F, people who were HIV negative.

Similar articles

References

    1. World Health Organization. Global tuberculosis report 2022. Available from: https://www.who.int/publications/i/item/9789240061729; accessed 2023 Jan 14.
    1. Harries AD, Schwoebel V, Monedero-Recuero I, Aung TK, Chadha S, Chiang CY, et al.. Challenges and opportunities to prevent tuberculosis in people living with HIV in low-income countries. Int J Tuberc Lung Dis. 2019;23(2):241–251. doi: 10.5588/ijtld.18.0207 - DOI - PubMed
    1. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV 2015. Available from: https://www.who.int/publications/i/item/9789241509565; accessed 2023 Jan 14. - PubMed
    1. Zachariah R, Bemelmans M, Akesson A, Gomani P, Phiri K, Isake B, et al.. Reduced tuberculosis case notification associated with scaling up antiretroviral treatment in rural Malawi. Int J Tuberc Lung Dis. 2011;15(7):933–937. doi: 10.5588/ijtld.10.0666 - DOI - PubMed
    1. Kanyerere H, Girma B, Mpunga J, Tayler-Smith K, Harries AD, Jahn A, et al.. Scale-up of ART in Malawi has reduced case notification rates in HIV-positive and HIV-negative tuberculosis. Public Health Action. 2016;6(4):247–251. doi: 10.5588/pha.16.0053 - DOI - PMC - PubMed

Publication types

Associated data